Flunitrazepam

# Research Output: Flunitrazepam

## Chemical Identity

**PubChem CID:** 3380 (api_verified via PubChem lookup) [Ref 1 — implied by PubChem CID search]

| Property | Value | Source |
|---|---|---|
| Molecular formula | C₁₆H₁₂FN₃O₃ | PubChem CID 3380 |
| Molecular weight | 313.28 g/mol | PubChem CID 3380 |
| IUPAC name | 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one | PubChem CID 3380 |
| InChIKey | PPTYJKAXVCCBDU-UHFFFAOYSA-N | PubChem CID 3380 |
| CAS number | 1622-62-4 | Web retrieval (ChemicalBook, Cayman Chemical) |
| Roche code | Ro 5-4200 | Web retrieval (Cayman Chemical) |
| SMILES | CN1C(=O)CN=C(c2ccccc2F)c3cc(ccc13)[N+](=O)[O-] | Web retrieval (ChemicalBook) |
| Melting point | 166–167°C (some sources: 170–172°C) | Web retrieval (ChemicalBook) |
| pKa | 1.8 (uncertain) | Web retrieval (ChemicalBook) |
| Protein binding | ~95.8% (free fraction 4.20 ± 0.34%) | Calvo et al. 1989 [Ref 30] |
| Appearance | White crystalline powder (neat solid) | Web retrieval |

**Seed data discrepancies:** The brief listed SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID as blank. All five have now been sourced and verified. The molecular formula (C₁₆H₁₂FN₃O₃), molecular weight (313.28), and IUPAC name match the brief's systematic name exactly. PubChem CID 3380 confirmed via API.

**Stereochemistry:** Flunitrazepam does not possess a classical chiral center in the diazepine ring as configured; it is marketed and used as a single compound with no clinically relevant stereoisomerism documented in the published literature. No specific information on active isomers was found. ⚠️ FLAG: This requires editorial confirmation.

---

## Pharmacology

### Mechanism of Action

Flunitrazepam is a benzodiazepine that acts as a **positive allosteric modulator (PAM) at the GABA-A receptor**, binding at the classical benzodiazepine site located at the α⁺/γ₂⁻ extracellular interface of the heteropentameric receptor complex. Like all classical benzodiazepines, it requires the presence of both α and γ₂ subunits to bind with high affinity; α₆-containing receptors (which lack benzodiazepine sensitivity) are insensitive. Flunitrazepam enhances the frequency of chloride ion channel opening in response to GABA, potentiating inhibitory neurotransmission throughout the CNS.

Doyno & White (2021 [Ref 1]) specifically noted that **flunitrazepam has greater potency and higher affinity for the GABA-A receptor than most benzodiazepines**, distinguishing it from agents like diazepam and nitrazepam. This high potency at the benzodiazepine site contributes to its pronounced hypnotic efficacy at low doses (1–2 mg) and its abuse potential.

As a radioligand, [³H]flunitrazepam is one of the most widely used tools in GABA-A receptor research, which means an extensive body of literature characterizes the binding site properties — confirming that this site is on all α₁,₂,₃,₅-containing γ₂-subunit receptors. No specific Ki values for flunitrazepam at individual GABA-A subunit combinations were retrieved from primary publications during this research. ⚠️ FLAG: Ki/EC50 values at individual receptor subtypes were not confirmed from primary binding studies specific to flunitrazepam as test compound; most studies use it as a radioligand rather than testing it.

### Metabolic Pathway and CYP Enzymes

Flunitrazepam undergoes oxidative metabolism primarily via two cytochrome P450 pathways (Kilicarslan et al. 2001 [Ref 32]; Hesse et al. 2001 [Ref 33]):

**N-Demethylation → Desmethylflunitrazepam (N-desmethylflunitrazepam)**
- Principal enzymes: CYP2C19 (Km = 11.1 μM) and CYP3A4 (Km = 108 μM)
- Relative in vivo contributions: CYP2C19 ~63%, CYP3A4 ~37% at therapeutic concentrations (0.03 μM) [Ref 32]
- Desmethylflunitrazepam is pharmacologically active

**3-Hydroxylation → 3-Hydroxyflunitrazepam**
- Principal enzyme: CYP3A4 (Km = 34.0 μM; Km CYP2C19 = 642 μM)
- CYP3A4 accounts for **>80% of intrinsic clearance** via 3-hydroxylation [Ref 33]
- Strongly inhibited by ketoconazole (IC₅₀ = 0.11 μM) and ritonavir (IC₅₀ = 0.041 μM)

**Overall:** CYP3A is the dominant enzyme when both pathways are considered (Hesse et al. 2001 [Ref 33]). CYP2A6, CYP2B6, CYP2C9 can each contribute to N-demethylation to a lesser degree; CYP1A2, CYP2D6, and CYP2E1 are **not** involved [Ref 32].

A comprehensive urine metabolite study identified **25 metabolites** in total (13 Phase I, 12 Phase II) via LC-QE-HF-MS (Qin et al. 2019 [Ref 21]). Phase II metabolites include N-glucuronide and O-glucuronide conjugates. Key forensically relevant metabolites are:
- **7-Aminoflunitrazepam** (from nitro-group reduction) — primary forensic urine marker; produced postmortem in blood
- **7-Aminodesmethylflunitrazepam**
- **7-Acetamidoflunitrazepam**
- **7-Acetamidodesmethylflunitrazepam**

**Clinical implication of CYP polymorphism:** CYP2C19 poor metabolizers show altered metabolite ratios but in vivo study found this does not substantially alter overall flunitrazepam clinical effects (Gafni et al. 2003 [Ref 34]).

**CYP3A4 drug interactions:** CYP3A4 inhibitors (ketoconazole, ritonavir, other azole antifungals, macrolide antibiotics, grapefruit) are expected to produce clinically significant increases in flunitrazepam plasma concentrations. CYP3A4 inducers (rifampin, carbamazepine, phenytoin) would be expected to decrease exposure [Ref 33]. ⚠️ FLAG: Direct clinical studies of these interactions with flunitrazepam are not well-documented; inference is from enzyme data.

### Human Pharmacokinetics

**Bioavailability:**
Oral bioavailability from tablet and oral solution: **≥80%** (tablet and oral solution are bioequivalent). Suppository: ~50%. A three-compartment pharmacokinetic model was identified (Cano et al. 1977 [Ref 2]).

**Key PK parameters (from Lauven et al. 1981 [Ref 29] and Drouet-Coassolo et al. 1990 [Ref 28]):**

| Parameter | Value |
|---|---|
| Oral bioavailability (tablet) | ≥80% |
| Biological (distribution) half-life | ~4.5 hours |
| Elimination half-life | 22 ± 5 hours (healthy); 16–35 hours (range across studies) |
| Volume of distribution (V₁) | ~25 L |
| Volume of distribution (VdSS) | 80–100 L |
| Total plasma clearance | ~250 mL/min |
| Oral clearance | 3.5 ± 0.8 mL/min/kg |
| Plasma protein binding | ~95.8% (free fraction ~4.2%) |
| Tissue binding | >90% |

**Tmax:** Not retrieved from primary human PK studies during this research. Onset of clinical effects is described as 15–30 minutes after oral ingestion (Britannica [Ref 25]; Mattila & Larni 1980 [Ref 11]).

**Effect of liver disease:** Single-dose oral PK parameters did not differ significantly between healthy subjects and patients with hepatitis or cirrhosis; however, the expected increase in free fraction during liver disease may lower therapeutic and toxic thresholds (Drouet-Coassolo et al. 1990 [Ref 28]).

**Effect of protein displacement:** Fatty acids (e.g., from heparin-induced lipolysis) displace flunitrazepam from albumin binding sites, increasing the free fraction from ~4.2% to as high as 22% with high fatty acid concentrations (Calvo et al. 1989 [Ref 30]). ⚠️ FLAG: This pharmacokinetic interaction with heparin co-administration may be clinically relevant in acute care settings.

---

## History

Flunitrazepam was **developed in the 1960s by Hoffmann-La Roche** (Basel, Switzerland) under the research code Ro 5-4200, the same laboratory responsible for diazepam, nitrazepam, and the broader benzodiazepine class. The drug was synthesized as part of Roche's benzodiazepine research program, which had been largely initiated by Leo Sternbach in the late 1950s, though no published source directly attributes flunitrazepam specifically to Sternbach. ⚠️ FLAG: Primary attribution for flunitrazepam synthesis could not be confirmed from peer-reviewed literature; the Hoffmann-La Roche/Roche development origin is confirmed from secondary sources (Britannica [Ref 25]).

**Rohypnol** (the primary brand name) was first marketed in **Switzerland in the early 1970s** for treatment of severe insomnia and as a preoperative anesthetic agent (Britannica [Ref 25]). The drug was subsequently licensed across Europe, Latin America, and parts of Asia. It was never approved by the US FDA for any indication.

**Clinical use trajectory:**
- 1970s–1990s: Legitimate clinical use as hypnotic and anesthetic premedication. Mattila & Larni (1980 [Ref 11]) reviewed its properties comprehensively, describing it as superior to older hypnotics in insomnia and noting extensive anesthesiology applications.
- 1990s: Reports of recreational abuse and drug-facilitated sexual assault emerged prominently, particularly in the US where the drug began appearing illicitly despite never having been approved. Congressional hearings led to:
  - **1996:** Drug-Induced Rape Prevention and Punishment Act (US) [Ref 27] — imposed 20-year sentences for distributing flunitrazepam to commit violent crimes; gave flunitrazepam Schedule I-level trafficking penalties despite its Schedule IV classification.
- **1997–1998:** Roche reformulated Rohypnol tablets: added a blue dye that turns light-colored beverages blue when dissolved, reduced tablet strength from 2 mg to 1 mg, and made tablets less soluble (web retrieval [Ref 25]). However, generic versions available internationally do not contain this dye.
- 2000s–present: Regulatory withdrawal from most EU markets (France, Spain, Norway, Germany, UK). Still legally prescribed in some countries (parts of Latin America, Asia) for insomnia. Globally, its illicit profile has shifted somewhat as GHB gained greater DFSA prominence, but flunitrazepam remains a controlled substance and forensic concern (Hessler et al. 2025 [Ref 40, citing PMID 40798869]).

---

## Subjective Effects

### Published Controlled Studies

**Dose-response and euphoria:**
Roset et al. (2001 [Ref 38]) conducted three randomized, double-blind, placebo-controlled crossover trials in healthy male volunteers comparing slow-onset vs. fast-onset flunitrazepam administration at low (0.8 mg total), medium (1.25 mg), and high (2 mg) doses. Key findings:
- **Low dose:** Low-intensity pleasurable effects
- **Medium dose (fast onset):** Distinct **euphorigenic effects** — balance of pleasurable and unpleasant feelings; blunted by slow onset
- **High dose:** Unpleasant sedative effects dominated; pleasurable effects suppressed

Farré et al. (1996 [Ref 40]) in healthy volunteers found flunitrazepam 2 mg produced the **most intense disruptive psychomotor effects** of any condition and significant increases in "liking," "good effects," and "high" scales on ARCI — indicating higher abuse liability than typical benzodiazepines.

Farré et al. (1998 [Ref 39]) in methadone-maintained patients found **4 mg flunitrazepam produced significant euphoria** (ARCI-MBG scale increases) that was not seen at lower doses; triazolam did not produce this effect, reinforcing flunitrazepam's distinct abuse liability in opioid-dependent populations.

Bond et al. (1994 [Ref 41]) studied **intranasal (snorted) flunitrazepam**: detectable in venous blood within 5 minutes; subjects reported liking the effect; peak plasma concentrations comparable to oral/intramuscular at ~110 minutes.

**Sedation quantification:**
Lucchesi et al. (2003 [Ref 43]) characterized flunitrazepam-induced sedation using ERP, EEG, and behavioral measures, confirming neurophysiological correlates of benzodiazepine sedation.

**Anterograde amnesia:**
Ott et al. (1988 [Ref 18]) in a double-blind, placebo-controlled study (40 healthy men): **2 mg flunitrazepam produced the greatest anterograde memory impairment** compared to lormetazepam and placebo. Pre-drug material was not impaired (no retrograde amnesia); material learned before dosing showed slight facilitation ("promnesic" effect). The amnestic effect was dose-dependent.

Liebrenz et al. (2016 [Ref 14]) in a qualitative study of high-dose benzodiazepine users: **anterograde amnesia was especially pronounced when short-acting benzodiazepines were combined with alcohol**; users described being victimized and engaging in violent behavior during amnestic periods.

**Clinical descriptions of effects profile:**
From Mattila & Larni (1980 [Ref 11]), Doyno & White (2021 [Ref 1]), and Schwartz et al. (2000 [Ref 9]):
- Rapid onset of sedation and hypnosis (15–30 minutes)
- Anterograde amnesia (potent; enables recall blackout at therapeutic doses)
- Muscle relaxation
- Anxiolysis
- Disinhibition
- Motor impairment (dose-dependent)
- Residual morning-after psychomotor impairment (comparable to nitrazepam/flurazepam)
- No marked cumulative effect with brief therapeutic use

**Effects taxonomy mapping (from published literature):**

| Effect slug | Basis | Evidence source |
|---|---|---|
| sedation | Controlled studies | [Ref 1], [Ref 11], [Ref 38] |
| amnesia | Controlled studies | [Ref 18], [Ref 14] |
| memory-suppression | Anterograde amnesia studies | [Ref 18], [Ref 14] |
| motor-control-impairment | Psychomotor testing | [Ref 40], [Ref 39] |
| muscle-relaxation | Clinical review | [Ref 1], [Ref 11] |
| anxiety-suppression | Mechanism/class effect | [Ref 1] |
| disinhibition | Case studies, controlled trials | [Ref 17], [Ref 40] |
| confusion | Case reports, forensic studies | [Ref 15], [Ref 17] |
| cognitive-euphoria | Controlled studies | [Ref 38], [Ref 39] |
| cognitive-impairment | Controlled studies | [Ref 40], [Ref 43] |
| respiratory-depression | Fatal cases, animal studies | [Ref 12], [Ref 37] |
| bodily-heaviness | Clinical description | [Ref 1] |
| dizziness | Clinical review | [Ref 25] |
| nausea | Clinical context (class effect) | [Ref 1] |
| delusions-of-sobriety | Forensic case reports | [Ref 14] |
| dreaming-enhancement | GABA-A hypnotic class effect | [Ref 1] |
| thought-deceleration | Class mechanism | [Ref 1] |
| analysis-suppression | Class mechanism | [Ref 1] |
| language-suppression | Forensic case reports | [Ref 17] |
| emotional-suppression | Clinical review | [Ref 1] |
| irritability | Withdrawal/case reports | [Ref 24] |
| compulsive-redosing-urge | Abuse liability data | [Ref 22] |
| abnormal-heartbeat | Class adverse effect | [Ref 1] |
| seizure-threshold-reduction | Withdrawal effect | [Ref 10], [Ref 24] |
| tactile-euphoria | Subjective reports | [Ref 38] |
| motivation-suppression | Sedation/cognitive suppression | [Ref 1] |
| thought-disorganization | High-dose effects | [Ref 17] |
| dry-mouth | Class adverse effect | [Ref 1] |
| anxiety | Rebound/withdrawal effect | [Ref 24] |

**Effect intensity/frequency assessments:** The community seed data lacks intensity and frequency values for all 27 effects. Based on the controlled literature:
- **Sedation**: High intensity, very common (near-universal at therapeutic doses)
- **Memory-suppression/amnesia**: High intensity, common at ≥1 mg
- **Motor-control-impairment**: Moderate-high, common at ≥2 mg
- **Cognitive-euphoria**: Moderate, dose- and population-dependent (more common in opioid users)
- **Respiratory-depression**: High intensity but primarily at overdose/combination doses
- **Anxiety-suppression**: High intensity, common (therapeutic mechanism)
- **Disinhibition**: Moderate-high, common

**Duration data from controlled studies:**
- Onset: 15–30 minutes oral (Britannica [Ref 25]; Mattila & Larni [Ref 11])
- Total effects: 4–8 hours (consistent with elimination half-life of ~22 hours but with deeper sedation resolving earlier)
- Aftereffects: Morning-after residual psychomotor impairment documented (Mattila & Larni 1980 [Ref 11])
- The seed DB duration values (onset 20–30 min, total 4–8 h, aftereffects 2–24 h) are consistent with the literature.

---

## Safety & Toxicity

### Overdose and Lethal Cases

Drummer et al. (1993 [Ref 12]) documented **8 deaths in Victoria, Australia** in a 2-year period attributable to flunitrazepam:
- 4 deaths: flunitrazepam as sole agent — very high 7-aminoflunitrazepam concentrations (mean 0.45 mg/L postmortem)
- 4 deaths: flunitrazepam + ethanol combination (mean ethanol 1.6 g/L; 7-aminoflunitrazepam mean 0.16 mg/L)
- Pathological findings at autopsy: none (no organ-specific damage)
- Conclusion: **Flunitrazepam can cause death in the absence of other drugs or significant disease**; ethanol substantially reduces the lethal threshold

Namera et al. (2012 [Ref 13]): Fatal case with high-dose flunitrazepam + triazolam combination. Blood 7-aminoflunitrazepam concentration: 1,270 ng/g. Multiple phase I and II metabolites identified.

### LD50 and Therapeutic Index

No published human LD50 data found. Animal LD50 data was not retrieved from primary studies during this research. ⚠️ FLAG: Specific LD50 (species, route) not sourced from primary literature.

### Respiratory Depression

The principal life-threatening mechanism is **respiratory depression**, compounded dramatically by co-ingestion of other CNS depressants (Doyno & White 2021 [Ref 1]). This occurs via:
1. Flunitrazepam alone at very high doses — demonstrated in the 8 Australian fatal cases [Ref 12]
2. **Ethanol + flunitrazepam** — pharmacodynamic synergy (Drummer et al. 1993 [Ref 12]; Schwartz et al. 2000 [Ref 9])
3. **Opioid + flunitrazepam** — pharmacodynamic synergy; documented deaths in France from buprenorphine + flunitrazepam combinations (Mégarbane et al. 2006 [Ref 36]); animal data confirms respiratory depression is the mechanism (Megarbane et al. 2005 [Ref 37])

The interaction with buprenorphine is strictly **pharmacodynamic** (not pharmacokinetic) — flunitrazepam does not alter buprenorphine distribution to the brain (Kilicarslan & Sellers 2000 [Ref 35]; Megarbane et al. 2005 [Ref 37]).

### Organ Toxicity

No significant organ pathology was identified at autopsy in any of the 8 overdose deaths (Drummer et al. 1993 [Ref 12]), suggesting toxicity is primarily CNS/respiratory rather than direct organ damage. Prenatal exposure in mice resulted in histological changes to ovarian follicles (OpenAlex result — not selected for primary citation due to animal-only data and limited relevance). ⚠️ FLAG: Chronic organ toxicity in humans not well-characterized in the retrieved literature.

### Psychological Risks

Published case reports document that flunitrazepam intoxication (particularly with alcohol) is associated with:
- **Violent criminal behavior** in forensically vulnerable individuals (Dåderman et al. 2002 [Ref 17]; Dåderman et al. 2003 [Ref — PMID 14550609])
- **Impaired judgment and decision-making**
- **Victimization** during amnestic periods (Liebrenz et al. 2016 [Ref 14])

---

## Harm Reduction

### Detection and Identification

- The reformulated Rohypnol tablet (post-1997) contains a blue dye that turns light-colored beverages blue (web retrieval). Generic versions do NOT contain this dye.
- Portable Raman spectroscopy has been demonstrated for in-situ detection in beverages within 10 seconds (Ali & Edwards 2017 [Ref — PMID 26990972]).
- Electrochemical screen-printed sensors can detect flunitrazepam in untreated spirits at sub-mg/L levels (multiple analytical chemistry publications 2019–2022; PMIDs 32933037, 35195989).
- Standard immunoassay (CEDIA) screens are unreliable at low doses — only 23/102 urine samples from 2.0 mg doses were CEDIA-positive in a controlled study; 0/all samples from 0.5 mg dose were detected (Forsman et al. 2009 [Ref 19]). ⚠️ FLAG: Forensic labs should use LC-MS/MS, not immunoassay, for reliable flunitrazepam/metabolite detection.

### Drug Interaction Warnings

**Absolutely contraindicated combinations:**
1. **Opioids (especially buprenorphine)** — pharmacodynamic synergy causing respiratory depression not reversible by naloxone [Refs 35, 36, 37]
2. **Alcohol** — synergistic CNS and respiratory depression; substantially reduces lethal threshold [Ref 12]
3. **Other benzodiazepines** — additive sedation and respiratory depression
4. **Other CNS depressants** (barbiturates, antihistamines, antipsychotics, muscle relaxants)

**CYP3A4 inhibitor interactions:**
Drugs that inhibit CYP3A4 (ketoconazole, ritonavir, erythromycin, clarithromycin, grapefruit juice) will increase flunitrazepam plasma concentrations [Ref 33]; clinical significance not yet established from direct human studies.

### Harm Reduction Specific to DFSA Context

- Victims of suspected flunitrazepam exposure should have **urine (not just blood)** collected promptly — 7-aminoflunitrazepam is detectable up to 240+ hours in urine at 2 mg dose (Forsman et al. 2009 [Ref 19]) vs. short detection window in blood [Ref 8]
- Hair sampling is valid up to 28+ days post-ingestion for 7-aminoflunitrazepam (Negrusz et al. 2001 [Ref 8])
- In DFSA investigations, the metabolite ratio 7-aminodesmethylflunitrazepam:7-aminoflunitrazepam can help estimate time of ingestion (Forsman et al. 2009 [Ref 19])

### Emergency Response

- **Flumazenil** (benzodiazepine antagonist) reverses flunitrazepam CNS effects by competitive displacement from the BZD binding site (Klotz 1988 [Ref — PMID 2842128])
- **CAUTION:** In buprenorphine + flunitrazepam combination poisoning, respiratory depression is not fully reversed by flumazenil alone — the opioid component also requires management [Ref 36]
- Supportive care (airway protection, mechanical ventilation) is the primary emergency intervention

---

## Tolerance & Dependence

### Tolerance

Tolerance to flunitrazepam's sedative/hypnotic effects develops with repeated use. In squirrel monkeys receiving 1 mg/kg orally for 18 consecutive days (Martin et al. 1995 [Ref 10]):
- Tolerance to loss of righting reflex developed **rapidly** (within days)
- Tolerance to sleep effects developed **more slowly**
- Tolerance to muscle relaxation was **minimal**

Lader (1994 [Ref 24]) reviewed benzodiazepine tolerance broadly, noting that tolerance develops via adaptive changes at GABA-A receptors (functional uncoupling of GABA and BZD binding sites persists after withdrawal, per Svob Strac et al. 2008 [Ref — PMID 18955034]).

The seed data states "tolerance builds within a couple of days of continuous use" — consistent with the rapid tolerance to righting reflex in the primate model [Ref 10], though the translational evidence for a precise "couple of days" timeline in humans is not from a primary clinical study. ⚠️ FLAG: Human-specific tolerance timeline not confirmed from primary clinical literature; primate data is consistent with rapid onset.

**Full tolerance reset: 10.5 days** — stated in seed data. Not verified against published source during this research. ⚠️ FLAG: This value should be verified; it may be derived from cross-reference with diazepam receptor recovery studies.

### Cross-Tolerance

Cross-tolerance with all benzodiazepines is expected from shared GABA-A receptor mechanism. Cross-tolerance with ethanol and barbiturates has also been documented in animal models (Toki et al. 1996 [Ref — PMID 8659687]).

### Physical Dependence

Physical dependence was confirmed in non-human primates after 18 days of daily administration. Flumazenil-precipitated withdrawal produced convulsions in 1/4 monkeys after day 9 and 3/4 monkeys after day 18 (Martin et al. 1995 [Ref 10]). No spontaneous withdrawal signs were observed in a subsequent 3-week drug-free period in the primate model.

Lader (1994 [Ref 24]) describes benzodiazepine withdrawal as comprising: **anxiety, insomnia, perceptual disturbances (photophobia, hyperacusis), feelings of unsteadiness, and in severe cases, seizures**. Onset is 2–10 days after cessation depending on half-life. Approximately one-third of long-term users experience a recognizable withdrawal syndrome even with tapering.

Benzodiazepine withdrawal seizures have been documented in NCSE (nonconvulsive status epilepticus) following abrupt BZD cessation (Mayà et al. 2026, PMID 41454790 — flunitrazepam-specific data not retrieved; class-level evidence).

### Abuse Liability

Griffiths & Johnson (2005 [Ref 22]) ranked flunitrazepam among the **higher-abuse-potential benzodiazepines** based on: reinforcing effects in preclinical and clinical studies, documented abuse prevalence, acute sedation/memory impairment, and overdose lethality.

In a methadone maintenance program in Israel, **92.9% of benzodiazepine abusers chose flunitrazepam** as their primary BZD — higher than diazepam (54.3%) and oxazepam (38.6%) (Gelkopf et al. 1999 [Ref 23]).

Multiple routes of abuse have been documented: oral (swallowing), intranasal (snorting), and intravenous injection (Gelkopf et al. 1999 [Ref 23]; Bond et al. 1994 [Ref 41]).

---

## Interactions

### With Opioids (Critical)

The buprenorphine + flunitrazepam combination is responsible for multiple documented deaths in France, where both drugs were legally prescribed (Mégarbane et al. 2006 [Ref 36]). Mechanism:
- **Purely pharmacodynamic synergism** — additive CNS/respiratory depression
- Not a pharmacokinetic interaction (flunitrazepam does not inhibit buprenorphine metabolism or distribution) [Refs 35, 37]
- Buprenorphine's partial agonist ceiling effect on respiratory depression is overwhelmed by concomitant benzodiazepine GABAergic depression
- **Not reversed by naloxone** (buprenorphine's partial antagonist/high-affinity component)
- All opioids combined with flunitrazepam pose similar risk

### With Ethanol

Synergistic CNS and respiratory depression. In the Australian fatal case series, ethanol blood levels of ~1.6 g/L were sufficient to render lethal flunitrazepam concentrations substantially lower than in alcohol-free cases (Drummer et al. 1993 [Ref 12]).

### With CYP3A4 Inhibitors

Ketoconazole reduces 3-hydroxyflunitrazepam formation to <10% of control values (IC₅₀ 0.11 μM); ritonavir similarly potent (IC₅₀ 0.041 μM) (Hesse et al. 2001 [Ref 33]). Clinical consequence: increased flunitrazepam exposure and prolonged/deepened effects expected when co-administered with:
- Azole antifungals (ketoconazole, itraconazole, fluconazole)
- HIV protease inhibitors (ritonavir, lopinavir/r)
- Macrolide antibiotics (erythromycin, clarithromycin)
- Grapefruit juice (chronic)

### With Flumazenil

Flumazenil competitively reverses all BZD-site effects; however, re-sedation may occur given flumazenil's short half-life (0.7–1.3 h) vs. flunitrazepam's long elimination half-life (22 h) (Klotz 1988 [Ref — PMID 2842128]). Repeated flumazenil dosing may be required.

### With Heparin

Heparin administration elevates free fatty acids which displace flunitrazepam from albumin, increasing free fraction from ~3.7% to ~6.2% — potentially increasing pharmacodynamic effects in acute care settings (Calvo et al. 1989 [Ref 30]).

---

## Legal Status

| Jurisdiction | Status | Notes |
|---|---|---|
| United States | Schedule IV, but Schedule I-level trafficking penalties | Not FDA-approved; 20-year sentence for distribution to commit violence (Drug-Induced Rape Prevention Act 1996) [Ref 27] |
| United Kingdom | Class C / Schedule 3 | More restricted than other BZDs; withdrawn from active market |
| Australia | Schedule 8 | Restricted; all other BZDs are Schedule 4 |
| Canada | Controlled substance, restricted | Sale banned |
| Germany | Anlage III Betäubungsmittel | Marketable under specific provisions; largely withdrawn |
| France, Spain, Norway | Withdrawn from market | All BZD still legal but Rohypnol product no longer sold |
| International (UN) | Schedule IV | 1971 UN Convention on Psychotropic Substances |

Sources: web retrieval (DEA [Ref 26], Congressional record [Ref 27], international regulatory sources).

---

## Clinical Trials

**NCT00707915** — "Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons"
- Status: COMPLETED
- Phase: Phase 4
- Sponsor: Minamihanno Hospital (Japan)
- Condition: Adverse effects of benzodiazepine hypnotics

**NCT02648776** — "Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly"
- Status: UNKNOWN
- Phase: Not specified
- Sponsor: China Medical University Hospital
- Condition: Sleep disorders

Note: Neither trial is specifically a flunitrazepam efficacy trial; both address broader benzodiazepine hypnotic drug class questions.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. Proceeding with standard research findings only.

---

## Gaps & Flags

### Safety-Critical Values Not Confirmed by Published Sources

1. ⚠️ **LD50 / Therapeutic Index:** No primary published LD50 data retrieved for flunitrazepam in any species. Oral LD50 in rodents likely exists in early toxicological literature but was not accessed during this research. The brief states "acute toxicity: high" — consistent with the case series evidence [Ref 12] but not a formally published LD50 value.

2. ⚠️ **Full tolerance reset time (10.5 days):** This specific value from the seed data was not verified against a published primary source. It may represent a calculation from cross-reference with receptor recovery kinetics or benzodiazepine equivalence tables.

3. ⚠️ **Dose range safety-critical validation:** The dose ranges in the seed data (Threshold 0.2 mg, Light 0.5–1 mg, Common 1–3 mg, Strong 3–4 mg, Heavy 4+ mg) are consistent with controlled study doses (0.5 mg, 1 mg, 2 mg, 4 mg used in Farré et al. [Refs 39, 40]). They are clinically plausible but not explicitly stated as dose range thresholds in a primary pharmacological study.

### Contradictions Between Seed Data and Published Sources

4. ✅ **Seed data characterization "emerging":** Flunitrazepam is a well-studied substance with a large body of literature dating to the 1970s. The "emerging" characterization in the DB is incorrect for this substance from a scientific standpoint. The editorial team should consider changing this to "established" or "well-studied." ⚠️ FLAG for human review.

5. ✅ **Missing PubChem CID, formula, weight, SMILES, InChIKey:** All now sourced and verified. CID 3380, C₁₆H₁₂FN₃O₃, 313.28 g/mol, PPTYJKAXVCCBDU-UHFFFAOYSA-N.

6. ⚠️ **Seed ROA "primary: oral, known: oral":** The literature documents intranasal and intravenous abuse routes as well (Bond et al. 1994 [Ref 41]; Gelkopf et al. 1999 [Ref 23]). The "known ROAs" field should probably include insufflation and intravenous (abuse routes) if abuse contexts are documented.

### Areas Relying on Class Inference Rather Than Substance-Specific Data

7. ⚠️ **Specific Ki binding affinity values:** No Ki values for flunitrazepam at specific GABA-A receptor subunit combinations (e.g., α₁β₂γ₂) retrieved from primary literature testing flunitrazepam as the active ligand. Flunitrazepam is ubiquitously used AS a radioligand, but data on its own binding constants at specific subtypes was not located.

8. ⚠️ **Sleep architecture EEG studies:** No EEG polysomnography studies of flunitrazepam-induced sleep changes were retrieved from PubMed, despite such studies likely existing in the 1970s–1990s literature. The review by Mattila & Larni [Ref 11] describes "quiet sleep without interruptions" but without polysomnographic detail.

9. ⚠️ **Stereochemistry:** No documentation of clinically relevant stereoisomerism found. Stated as single compound with no enantiomer considerations in the literature reviewed.

10. ⚠️ **Tmax value:** Not directly stated in any retrieved primary human PK study. Clinical onset 15–30 minutes suggests Tmax around 1–2 hours, but this is not confirmed from a formal PK absorption study.

### Remaining Data Gaps

11. **Synthesis/discovery attribution:** Hoffmann-La Roche origin confirmed; specific chemist and year of synthesis not confirmed from primary literature.

12. **Physical property logP:** Not retrieved from accessible sources.

13. **Contraindications in the database are blank:** Published contraindications include: sleep apnea, myasthenia gravis, severe hepatic impairment (standard BZD class contraindications); pregnancy (teratogenic risk established for benzodiazepine class); history of substance dependence. ⚠️ FLAG: These should be added to the database.

14. **Dose range for non-oral routes:** No controlled human studies of intranasal or intravenous dose-response from a safety/pharmacology perspective were retrieved.